Innovent Biologics: Post-2H25 Earnings IR Discussion
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Bernstein maintains an Outperform rating on Innovent Biologics (1801.HK) with a target price of HK$120.00, implying 36% upside from the closing price of HK$88.20. Following an investor relations discussion with Head of IR Wendy Song, the firm believes the market underestimates the company's transition from a biotech to an integrated biopharmaceutical company and the catalyst potential of its early-stage pipeline.
Innovent guides for RMB 20 billion in product revenue by 2027, split evenly between oncology and comprehensive biopharmaceuticals. Near-term growth is driven by mazdutide, tafolecimab, teprotumumab, and picankibart, while the longer-term outlook relies on early-stage assets like IBI363. The company expects roughly $200–300 million in annual collaboration revenue over the next four to five years from existing partnerships with Takeda and Eli Lilly.
Mazdutide has shown strong month-over-month growth year-to-date, with volume expansion offsetting price adjustments, and management reaffirmed a gross margin of around 85%. Looking ahead, 2026 is packed with potential catalysts across major medical conferences, including ASCO, EASD, and ESMO. Management has not yet finalized which assets will advance into global Phase 3 trials independently. However, Bernstein views this as a realistic and near-term opportunity. Key risks include negative clinical trial outcomes, slower-than-expected sales, and biosimilar market share underperformance.